(Total Views: 513)
Posted On: 12/28/2020 11:53:01 AM
Post# of 153992
Re: ClosetInvestor #69933
first patient first visit metric was met for the Company’s Phase 2 clinical trial
I just do not understand this language. It obfuscates the headline about enrollment. NASH as per my understanding of LL's MoA is one disease where very strong efficacy is a very likely outcome.
And we only have one patient who "met the first visit metric"???
WTH is the "first visit metric"?? It doesn't sound like the functional equivalent of "... the first trial participant has been treated with LL."
I just do not understand this language. It obfuscates the headline about enrollment. NASH as per my understanding of LL's MoA is one disease where very strong efficacy is a very likely outcome.
And we only have one patient who "met the first visit metric"???
WTH is the "first visit metric"?? It doesn't sound like the functional equivalent of "... the first trial participant has been treated with LL."
(1)
(0)
